About this item
Product details
Glem-Lin MXR from Nabiqasim is a maximum-strength, triple-combination therapy designed for comprehensive management of Type 2 Diabetes. Each extended-release tablet contains three powerful medications: Empagliflozin 25 mg (maximum SGLT2 inhibitor dose), Linagliptin 5 mg (DPP-4 inhibitor), and Metformin 1000 mg (Biguanide). This advanced formulation provides robust, multi-mechanism glycemic control in a single once-daily tablet, making it ideal for patients requiring intensive treatment with maximum efficacy. Maximum Strength Triple Therapy: Combines the highest recommended dose of Empagliflozin with therapeutic doses of Linagliptin and Metformin Three-Pronged Glucose Control: Empagliflozin 25 mg: Maximum SGLT2 inhibition for optimal glucose excretion through urine Linagliptin 5mg: Enhances insulin secretion and reduces glucagon production Metformin 1000mg XR: Reduces liver glucose production and improves insulin sensitivity Cardiovascular & Renal Protection: Empagliflozin provides proven cardiovascular risk reduction and kidney protection benefits Extended-Release Advantage: Improved gastrointestinal tolerance with sustained Metformin delivery Treatment Simplification: Single-tablet regimen enhances adherence for complex diabetes management Composition Each film coated tablet contains: Empagliflozin : 25 mg Linagliptin: 5 mg Metformin HCI USP (as extended release core): 1000 mg Directions for Use As directed by the physician
- Medicines
- 14 Film Coated Tablets
- 1 variant
- Protected Dastak checkout
Know before you buy
Specifications
- Department
- Health
- Subcategory
- Medicines
- Brand
- Nabiqasim
- SKU
- 08964003524227
- Variant
- 14 Film Coated Tablets
- Tags
- Empagliflozin, Linagliptin, Medicine, Metformin
- Condition
- New
Customer feedback
Ratings & reviews
For help with a purchase, open your orders or contact Dastak support.
